Evidence map›Paper›PMID 34239182›Full record

ArticleNagoya journal of medical science2021

The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis.

Jiudan Zhang, Ye Chen, Jian Wang, Hong Xia, Yang Zheng

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Nagoya journal of medical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jiudan ZhangDepartment of Endocrinology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Ye ChenDepartment of Internal Medicine, Nanjing Municipal Center for Prevention and Treatment of Occupational Disease, Nanjing, China.
Jian WangDepartment of Endocrinology, Jinling Hospital, The Affiliated Hospital of Nanjing University, Nanjing, China.
Hong XiaDepartment of Endocrinology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Yang ZhengDepartment of Endocrinology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Zhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucocorticoid use may trigger secondary diabetes or exacerbate hyperglycemia in patients with diabetes mellitus (DM). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of patients with type 2 diabetes. Few reports mention liraglutide as a treatment for steroid-induced DM (SIDM). Here, we report a patient with SIDM and multiple sclerosis, for whom switching to liraglutide combined with metformin therapy improved glucose levels and ameliorated the symptoms of insulin allergy. Liraglutide may be useful for treating SIDM with insulin allergy.

Indexed as

Diabetes Mellitus, Type 2HypersensitivityMultiple SclerosisGlucocorticoidsHumansHypoglycemic AgentsInsulinsLiraglutideGlucocorticoidsHypoglycemic AgentsInsulinsLiraglutideinsulin allergyliraglutidemultiple sclerosissteroid-induced diabetes mellitus

Identifiers

PMID34239182
PMCPMC8236694
OpenAlexW3177913267

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.